Sign in Register

Drug class

LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer

The phrase "LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer" represents a descriptive formulary or compendial grouping rather than a single standardized pharmacological class, encompassing both gonadotropin-releasing hormone agonists and antagonists indicated for androgen deprivation therapy. Read more about LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer

28 drugs in this class 15 manufacturers

Advertisement

Related classes & indications

Alkylating AgentsOncology & immunomodulators · 192 prescription drugs Antirheumatic Agents (DMARDS, non-Biologic)Oncology & immunomodulators · 179 prescription drugs Advanced Prostatic CarcinomaTop indication · 92 prescription drugs

Drugs in LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer

Showing 10–18 of 28 drugs

Filter & compare in the drug finder → Opens the drug finder with LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer preselected. Add indication or manufacturer filters there.

About LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer.

The phrase "LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer" represents a descriptive formulary or compendial grouping rather than a single standardized pharmacological class, encompassing both gonadotropin-releasing hormone agonists and antagonists indicated for androgen deprivation therapy.

These agents modulate pituitary gonadotropin-releasing hormone receptors: agonists induce receptor downregulation following an initial surge, whereas antagonists directly and competitively block the receptors without an initial surge.

Both mechanisms ultimately suppress luteinizing hormone and follicle-stimulating hormone secretion, reducing serum testosterone to castrate levels to inhibit androgen-dependent tumor growth.

Clinically, these medications are primarily indicated for the management of advanced, metastatic, or locally advanced prostate cancer.